FindTrial
Sign In

Risk-stratification Treatment Directed by Minimal Residual Disease in Acute Myeloid Leukemia with t(8;21) in First Complete Remission

Risk-stratification Treatment Directed by Minimal Residual Disease in Acute Myeloid Leukemia with t(8;21) in First Complete Remission

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-12002406
Enrollment
Unknown
Registered
2012-08-07
Start date
2005-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia with t(8

Interventions

1:risk-directed treatment

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) newly diagnosed AML patients with a positive t(8;21) cytogenetic result or RUX1/RUX1T1 transcripts; (2) between 14 and 60-years-old; (3) in first complete remission (CR1); (4) no contraindications to consolidation chemotherapy or HSCT.

Exclusion criteria

Exclusion criteria: (1) relapsed AML patients with a positive t(8;21) cytogenetic result or RUX1/RUX1T1 transcripts; (2) less than 14 or more than 60-years-old; (3) in first complete remission (CR1); (4) no contraindications to consolidation chemotherapy or HSCT.

Design outcomes

Primary

MeasureTime frame
relapse;DFS;—

Contacts

Public ContactXiao-Jun Huang
xjhrm@medmail.com.cn+86 13701389625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 23, 2026